Chen-Xu M et al
Insurance and savings cards can drop patient costs dramatically, sometimes to $0$25, but that depends entirely on coverage
30 Carney JA, Gordon H, Carpenter PC, Shenoy BV, Go VL
Reddys Laboratories, Emcure Pharmaceuticals, Glenmark Pharmaceuticals, Lupin, MSN, Sun Pharma, Torrent Pharmaceuticals, USV, Zydus) 3 companies are using a vial-based format (Eris Lifesciences, Glenmark Pharmaceuticals, Natco Pharma announced a pen for April) 1 company has launched the oral tablet (Torrent Pharmaceuticals) Two companies are taking a broader approach: Glenmark Pharmaceuticals: vial and pen Torrent Pharmaceuticals: pen and tablet China is powering Indias semaglutide generic entries Chinese manufacturers are a critical part of the supply chain behind Indian semaglutide launches not only at the API level, but also upstream in intermediates and key starting materials (Figure 4) : 8 companies (61%) show partial or full dependence on China 3 companies (23%) are fully reliant on China for API manufacturing 5 companies (38%) source APIs from two countries but all still include China Only 4 companies (31%) show no direct China exposure at the API manufacturing level Abbott and Emcure via Novo Nordisk in-licensing from Denmark MSN and Zydus with API manufacturing in India However, China dependency remains present even in some of these cases just further upstream
Many of our patients present with specific weight-related goals
